Katerina Chatzidionysiou

Author

Also Known As

A Chatzidionysiou, A. Chatzidionysiou, Aikaterina Chatzidionysiou, Aikaterini Chatzidionysiou, Chatzidionysiou, Katerina, Eva Baecklund, K Chatzidionysiou, K. Chatzidionysiou, Katarina Chatzidionysiou, Katarina F Niward

163

Publications

11.9K

Citations

H-Index

Concepts

All Affiliations

Karolinska Institutet Karolinska University Hospital Diakonhjemmet Hospital Helsinki University Hospital University of Copenhagen

About

Katerina Chatzidionysiou is an author at Karolinska Institutet specializing in medicine, rheumatology, and clinical trials.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	304
2	Rheumatology	3	3	260
3	Immunology	2	2	65
4	Orthopaedics	1	1	223
5	Autoimmune Disease	1	1	21

Katerina Chatzidionysiou

Publications

Citations

H-Index

Page 1

	Year	Citations
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update Josef S Smolen, Robert Landewé, Sytske Anne Bergstra, Annals of the Rheumatic Diseases	2022	1.6K
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial Ronald van Vollenhoven, Pierre Geborek, Kristina Forslind, The Lancet Rheumatoid DisorderRheumatologySystemic TreatmentRheumatic DiseasesClinical Trials	2012	223
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, Annals of the Rheumatic Diseases	2021	101
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries Delphine S. Courvoisier, Katerina Chatzidionysiou, Denis Mongin, Lara D. Veeken	2020	90
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration Katerina Chatzidionysiou, Elisabeth Lie, E L Nasonov, Annals of the Rheumatic Diseases	2011	76
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study Cem Gabay, Myriam Riek, Merete Lund Hetland, Annals of the Rheumatic Diseases	2015	70
Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register Katerina Chatzidionysiou, Johan Askling, Jonas Eriksson, Annals of the Rheumatic Diseases	2014	67
Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort N. Györi, Ioanna Giannakou, Katerina Chatzidionysiou, Lupus Science & Medicine	2017	61
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis Helga Radner, Katerina Chatzidionysiou, Elena Nikiphorou, Annals of the Rheumatic Diseases	2018	61
A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission Katerina Chatzidionysiou, Carl Turesson, Annika Teleman, RMD Open	2016	57

Page 1